US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone
The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
You may also be interested in...
Novo Nordisk’s cornerstone type 2 diabetes treatment Victoza is set to come under siege from the three largest generics manufacturers beginning in June 2024, after Sandoz became the last of the trio to sign a licensing agreement with the Danish originator that resolves patent-litigation proceedings.
A market opportunity has just opened up for Novo Nordisk’s ultra-fast acting mealtime insulin, Fiasp: its indications have just been extended to include younger EU patients who are aged more than one year.
Sales of injectable semaglutide shored up Novo's second quarter, but all eyes are on the expected launch of an oral version in the third quarter.